Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
More GEN Content From This Contributor:
- Columns: Quo Vadis Biofuels Projects?
- Columns: Weeds and Reeds - The Invasion of the Second Generation Biofuel Crops
- Columns: International Students in the U.S. - A Diminishing Pool of Talent for Biotech?
- Columns: Thanks a lot, Bernie Madoff!
- Columns: Stimulate This!
- Columns: Biosimilar Approval in the U.S. and Europe: How Similar Are They?
- Columns: The New Face of Pharma R&D?
- Columns: Change Is the Air
- Columns: Pharma and Biotech Will Follow the Rest of the Economic Downward Trend – a Defensive Play no Longer
- Columns: Bias in Pharma Studies Published by the FDA—Shocking!!!
- Columns: Quotas for Women in Science
- Columns: The End of Nationalism (At Least in Pharma)
- Columns: The Japanese Acquisition Binge
- Columns: The Death of the Blockbuster
- Columns: Insourcing vs. outsourcing: the Roche-Genetech deal
- Columns: The Food Crisis - Exacerbated by Demand for Biofuel?
- Columns: The FDA Scale-Up: Good for Big Pharma or Not?
- Columns: Is Europe's Biotech Pipeline Empty?
- Columns: Awakening the Chinese (biotech) dragon
- Columns: No soup for you (no more) - VC-backed companies shooting for SBIR eligibility
- Columns: Big Pharma & Big Government = Big Profits?
- Columns: Post-doctoral paupers
- Columns: The Valley of Death